Suppr超能文献

α2-巨球蛋白将纤溶酶原激活限制在RC2A白血病细胞表面。

Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

作者信息

Stephens R W, Tapiovaara H, Reisberg T, Bizik J, Vaheri A

机构信息

Department of Virology, University of Helsinki, Finland.

出版信息

Cell Regul. 1991 Dec;2(12):1057-65. doi: 10.1091/mbc.2.12.1057.

Abstract

Human RC2A myelomonocytic leukemia cells are able to activate the prourokinase (pro-u-PA) they secrete so that active u-PA is present both in serum-free conditioned medium from these cells, as well as on the cell surface. When the cells are grown in serum-containing medium, no u-PA activity can be found in the medium but active u-PA is found bound to the cell surface where it can generate bound plasmin. This distribution of u-PA activity was shown to be, first, the net result of slow inactivation of free active u-PA by serum inhibitor(s) and simultaneous rapid uptake of u-PA onto the cell surface. Binding to cells was at least six times faster than inactivation by 10% serum. The principal serum inhibitor of u-PA was identified as alpha 2-macroglobulin (alpha 2M), and prior inactivation of u-PA by purified human alpha 2M was also shown to prevent uptake of u-PA activity onto cells. Second, although endogenous u-PA could form covalent complexes with purified alpha 2M in the culture medium of RC2A cells, covalent alpha 2M complexes were not formed by u-PA on the cell surface; the u-PA taken up in this compartment was protected against alpha 2M inhibition. u-PA anchored to plastic surfaces via monoclonal antibodies to the amino-terminal region of u-PA was also protected against alpha 2M, suggesting that the protection of cell surface u-PA results from a steric effect. These results provide evidence as to how the active u-PA produced by leukemia cells can contribute to proteolytic activity on their cell surface in the presence of serum inhibitors.

摘要

人RC2A骨髓单核细胞白血病细胞能够激活它们所分泌的纤溶酶原激活剂(pro-u-PA),使得活性u-PA既存在于这些细胞的无血清条件培养基中,也存在于细胞表面。当细胞在含血清的培养基中生长时,培养基中未发现u-PA活性,但在细胞表面发现有活性u-PA,它能产生结合型纤溶酶。u-PA活性的这种分布首先被证明是血清抑制剂使游离活性u-PA缓慢失活以及u-PA同时快速摄取到细胞表面的净结果。与细胞的结合比10%血清导致的失活至少快6倍。u-PA的主要血清抑制剂被鉴定为α2-巨球蛋白(α2M),并且还表明纯化的人α2M预先使u-PA失活可防止u-PA活性摄取到细胞上。其次,尽管内源性u-PA可在RC2A细胞的培养基中与纯化的α2M形成共价复合物,但细胞表面的u-PA不会形成共价α2M复合物;在这个区室摄取的u-PA受到保护而免受α2M抑制。通过针对u-PA氨基末端区域的单克隆抗体锚定在塑料表面的u-PA也受到α2M的保护,这表明细胞表面u-PA的保护是由空间效应导致的。这些结果提供了证据,说明白血病细胞产生的活性u-PA在存在血清抑制剂的情况下如何有助于其细胞表面的蛋白水解活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9822/361905/34f624028316/cellregul00037-0097-a.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验